We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
How much money do salv have in the bank. Just asking as their being paid in shares ! Looking to buy. Trials cost money. Normally when the sp reaches a high if they need money for clinical trials if they get short on funds the go for a placing so I thought I'd ask. Not done much research on this one yet. Thanks
They know where this heading & will not be able to contain this for much longer. 80p+ seems primed to be breached then quickly onto £1+
How do people imagine portage will get their minority SH to vote though a deal at 250% premium without Salv knowing that big news is imminent re intensity
Exciting times! :)
Cancer tumour breakthrough with intensity therapeutics will absolutely BLOW the doors off. You won't in my opinion get a look in less then £3/4 if that. Under £1 = an absolute steal
Any idea when this deal is set to go through?
Easy money if ever I've seen. Looks a complete no brainner & 100% upside MIN from these levels. Should be £1.40 all day long & free float only 2 million = will MOVE very quickly indeed
Thought everyone said this one was about to rocket to 150p!
Therapeutics... fat fingers!
Commenting on the investment Jim Mellon, Chairman of FastForward, noted: "The results from Intensity Therapeutics' work continues to be so positive we had no hesitation taking up FFWD's pro rata entitlement in the Series B funding round. In addition, the Warrant granted to FFWD locks in a right for the Company to invest further funds at US$5.00 per share should results over the Summer continue to impress. We believe the Warrant will be of interest to UK based institutional investors and the Company plans to present, with Intensity management, the results of the IT-01 study to date to interested parties over the Summer." Lew Bender, President and CEO at Intensity Therapeutics was pleased FFWD participated in the Series B round: "We are delighted Fast Forward has committed to maintain its investment by participating in our Series B funding round. Our drug, INT230-6, continues to achieve excellent clinical results in study IT-01. The safety data generated to date indicate a dose escalation is possible. In addition, we see tumor response in multiple cancer types, even at the low doses administered. This round of funding is expected to help to advance our clinical program into Phase 2a." https://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/FFWD/13724466.html
CEO Portage Biotech: Dr. Declan Doogan has over 30 years of industry experience in both major pharma and biotech. He was the Senior Vice-President and Head of Worldwide Development at Pfizer, where many multibillion dollar programs were delivered (e.g., Viagra, Lipitor and Zoloft). He has held a number of executive positions in Pfizer in the US, the UK and Japan. Since leaving Pfizer in 2007 he has been engaged in executive roles in small pharma. Declan was CMO and acting CEO of Amarin (AMRN: Nasdaq), transforming it from a failing Neuroscience company to a vibrant cardiovascular company with a market capitalization of over one billion dollars before his departure. He has also been Chief Medical Officer for Prometheus Laboratories, a molecular diagnostics company in San Diego. Declan is also an investor in emerging biotechnology and technology companies. He holds a number of Board appointments, principally in pharma companies, and has also held professorships positions at Harvard School of Public Health, Glasgow University Medical School and Kitasato University (Tokyo). Declan received his medical degree from Glasgow University in 1975. He is a Fellow of the Royal College of Physicians and the Faculty Pharmaceutical Medicine and holds a Doctorate of Science at the University of Kent in the UK.
Nice overview of what Portage is all about: http://microcapspot.com/portage-biotech-setting-stage-growth-poised-double/1076/
77.5p on the ask now
Smart money is buying at current levels. Most will jump in closer towards £1.10/£1.20 always the case. I prefer buying now
Well, hopefully there will be more movement in the sp after the holiday period has ended ...
QF
That’s a classic sign of a paid deramper same message again and again..lol
Trading at ~50% of the offer price is a classic sign that shareholders don't believe in the deal. It's a pretty hefty risk premium.
Can see 80p soon. MM playing games. 2 million or less free float. Jim Mellon = leading investor & he is all over #salv
Portage Biotech and Boehringer Ingelheim Venture Fund participated in a Series A round that, in combination with non-dilutive funding from the National Institute of Health will allow Sentien to finish IND enabling studies and proceed to a Phase I trial in patients. A successful Phase I trial would significantly affect the valuation and could trigger a liquidity event.....
Free to SALV holders
Advertising for a Director of Manufacturing - The Director will develop a team to drive process engineering for future manufacturing needs through late-stage clinical trials and US commercialization. This requires tight collaborations with R&D, Quality and Regulatory to improve upon existing process and implement next-generation manufacturing.
According to ft the free float is only 20 pct or so, but could be even less then...
Free float is more like 2 million. This will be heading towards £1.40
Watch the video
vimeo.com/188019015
We get a share of this when Portage takeover SALV
They have been filling orders. £18.5k buy. Anything @ these levels a BARGAIN entry
£18.38k buy at 73.5p on the board now